FDA Updates on Sarepta Gene Therapy

Introduction to the Update

The Food and Drug Administration (FDA) has announced that it will be adding a new warning to a gene therapy for Duchenne’s muscular dystrophy due to its link with two patient deaths. This move comes after the therapy, developed by Sarepta Therapeutics, was found to potentially cause fatal liver failure.

Background on the Gene Therapy

The infused therapy, known as Elevidys, has been under FDA scrutiny since the first death was reported in March, followed by a second death in June. Initially, the FDA called for a halt on all shipments of the drug but later reversed this decision after facing opposition from patient families and activists. Elevidys is the first U.S.-approved gene therapy for Duchenne’s muscular dystrophy, a fatal muscle-wasting disease primarily affecting boys and young men.

Details of the FDA Warning

The FDA will add a boxed warning, the most serious type of warning, to alert doctors and patients about the risk of potentially fatal liver failure associated with Elevidys. This decision reflects the FDA’s commitment to ensuring the safety of treatments while also considering the needs of patients with severe diseases.

Limitations and Precautions

In addition to the boxed warning, the FDA is limiting the approved use of Elevidys to patients who are 4 years old and up and can still walk. Previously, the drug was allowed for use in immobile patients, who typically have more advanced disease. New labeling will recommend weekly liver function monitoring for the first three months of treatment, along with other precautionary measures to mitigate risks.

Impact on Sarepta Therapeutics

Elevidys is Sarepta’s best-selling product, and the recent concerns surrounding the drug have significantly impacted the company, leading to the announcement of 500 employee layoffs in July. However, following the FDA’s announcement, Sarepta Therapeutics Inc. shares rose 7.7% in trading, indicating improved visibility for investors regarding the company’s outlook.

Conclusion

The FDA’s decision to add a boxed warning to Elevidys and limit its use reflects a balanced approach to managing the risks and benefits of innovative treatments like gene therapy. While the news may pose challenges for Sarepta Therapeutics, it also underscores the importance of ongoing monitoring and evaluation of medical treatments to ensure patient safety.

FAQs

Q: What is Elevidys used for?

A: Elevidys is a gene therapy used to treat Duchenne’s muscular dystrophy, a fatal muscle-wasting disease that affects boys and young men.

Q: Why did the FDA add a warning to Elevidys?

A: The FDA added a boxed warning to Elevidys due to its association with potentially fatal liver failure, as evidenced by two patient deaths.

Q: What are the new limitations on the use of Elevidys?

A: The FDA has limited the use of Elevidys to patients who are 4 years old and up and can still walk, and recommends weekly liver function monitoring for the first three months of treatment.

Q: How has this affected Sarepta Therapeutics?

A: The concerns over Elevidys led to a significant impact on Sarepta Therapeutics, including layoffs, but the FDA’s announcement has provided clarity that has positively affected the company’s stock.

By MATTHEW PERRONE, Associated Press Health Writer

WASHINGTON (AP) — The Food and Drug Administration said Friday it will add a new warning and other limitations to a gene therapy for Duchenne’s muscular dystrophy that’s been linked to two patient deaths.

The infused therapy from Sarepta Therapeutics will carry a boxed warning — the most serious type — alerting doctors and patients to the risk of potentially fatal liver failure with the treatment, the FDA said in a release.

The one-time therapy, Elevidys, has been under FDA scrutiny since the company reported the first of two deaths of teenage boys in March. Following a second death reported in June, the FDA briefly called for halting all shipments of the drug. But the agency quickly reversed course after facing pushback from patient families and libertarian activists close to President Donald Trump.

Elevidys is the first U.S.-approved gene therapy for Duchenne’s muscular dystrophy, a fatal muscle-wasting disease that affects boys and young men.

In addition to the boxed warning, the FDA is also limiting the drug’s approved use to patients who are 4 years old and up and can still walk. Previously the FDA had allowed the drug’s use in immobile patients, who generally have more advanced disease.

New labeling will also recommend weekly liver function monitoring for the first three months of treatment, as well as other precautionary steps.

Elevidys is Sarepta’s best-selling product and recent headwinds against the drug have weighed heavily on the company and its stock. In July, the Cambridge, Massachusetts-based company announced it would lay off 500 employees.

Sarepta Therapeutics Inc. shares rose 7.7% in trading after the FDA announcement, reflecting improved visibility for investors about the company’s outlook.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.